

**BRIUMVI**  
**(ublituximab-xiiy)**

## **Pre - PA Allowance**

None

---

## **Prior-Approval Requirements**

**Age** 18 years of age and older

### **Diagnosis**

Patient must have the following:

1. Relapsing Multiple Sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease
  - a. Ineffective response due to continued clinical relapse, intolerance or contraindication to two or more MS drugs
    - i. Does not apply if the patient has advanced, progressive, or severe disease

**AND ALL** of the following:

1. Patient is not at risk for HBV infection **OR** patient is at risk for HBV infection and HBV infection has been ruled out or treatment for HBV infection has been initiated
2. Absence of active infection
3. Prescriber agrees to monitor levels of quantitative serum immunoglobulins
4. Prescriber agrees to pre-medicate with a corticosteroid, antihistamine, and/or antipyretic, as clinically indicated
5. **NOT** used in combination with other immune-modulating or immunosuppressive therapies, including immunosuppressant doses of corticosteroids
6. **NOT** used in combination with another MS disease modifying agent
7. **NOT** given concurrently with live vaccines or live attenuated vaccines
8. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Briumvi and for 6 months after the last dose

## **Prior - Approval Limits**

**Duration** 2 years

**BRIUMVI**  
**(ublituximab-xiiy)**

---

## **Prior – Approval *Renewal* Requirements**

**Age** 18 years of age and older

### **Diagnosis**

Patient must have the following:

1. Relapsing Multiple Sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease

**AND ALL** of the following:

1. Absence of active infection
2. Prescriber agrees to monitor levels of quantitative serum immunoglobulins
3. Prescriber agrees to pre-medicate with a corticosteroid, antihistamine, and/or antipyretic, as clinically indicated
4. **NOT** used in combination with other immune-modulating or immunosuppressive therapies, including immunosuppressant doses of corticosteroids
5. **NOT** used in combination with another MS disease modifying agent
6. **NOT** given concurrently with live vaccines or live attenuated vaccines
7. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Briumvi and for 6 months after the last dose

## **Prior - Approval *Renewal* Limits**

Same as above